Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451821 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL451615 | 0.90 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL449750 | 0.86 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL447864 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL452569 | 0.85 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL450045 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL450956 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL450403 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL453808 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 | |
| SCHEMBL450437 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTSMN1; SMN2TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | ALDH1A1 3161/4885KDM4E 3717/4885MAPT 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.